Octavio Espinoza - Dec 30, 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
Chief Financial Officer
Signature
/s/ Andrew Reardon, Attorney-in-Fact for Octavio Espinoza
Stock symbol
LGND
Transactions as of
Dec 30, 2022
Transactions value $
$15,615
Form type
4
Date filed
1/4/2023, 04:00 PM
Previous filing
Dec 27, 2022
Next filing
Feb 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Other $15.6K +275 +1.47% $56.78 18.9K Dec 30, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares acquired under Ligand's employee stock purchase plan. Voluntary reporting exemption under Rule 16b-3(c).